©The Author(s) 2025.
World J Hepatol. Dec 27, 2025; 17(12): 113658
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.113658
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.113658
Table 3 Summary of alanine aminotransferase in norursodeoxycholic acid and placebo groups at various visits, mean (95% confidence interval)
| Visit | norUDCA | Placebo | P value |
| Visit 1/baseline | 85.20 (81.34-89.06) | 82.09 (77.37-86.82) | 0.196 |
| Visit 3/week 6 | 36.51 (28.88-44.24) | 42.19 (31.49-52.89) | 0.395 |
| Visit 4/week 12 | 24.07 (21.01-27.13) | 30.59 (26.31-34.89) | 0.016 |
| Visit 5/week 18 | 23.99 (20.54-27.46) | 31.06 (26.21-35.92) | 0.021 |
| Visit 6/week 24 | 22.19 (18.13-26.25) | 29.74 (24.04-35.44) | 0.035 |
- Citation: Panuganti VK, Alluri CV, Mohammad J, Dundigalla MR, Madala PK, KSSVV S, Shaik A. Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients. World J Hepatol 2025; 17(12): 113658
- URL: https://www.wjgnet.com/1948-5182/full/v17/i12/113658.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i12.113658